Cargando…

Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs

BACKGROUND: It is currently unknown whether early immunomodulatory treatment in relapsing–remitting MS (RRMS) can delay the transition to secondary progression (SP). OBJECTIVE: To compare the time interval from onset to SP in patients with RRMS between a contemporary cohort, treated with first gener...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tedeholm, H, Lycke, J, Skoog, B, Lisovskaja, V, Hillert, J, Dahle, C, Fagius, J, Fredrikson, S, Landtblom, A-M, Malmeström, C, Martin, C, Piehl, F, Runmarker, B, Stawiarz, L, Vrethem, M, Nerman, O, Andersen, O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2013
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3652599/ https://www.ncbi.nlm.nih.gov/pubmed/23124789 http://dx.doi.org/10.1177/1352458512463764

Ejemplares similares

Short-term prediction of secondary progression in a sliding window: A test of a predicting algorithm in a validation cohort
por: Skoog, B, et al.
Publicado: (2019)

Searching for neurodegeneration in multiple sclerosis at clinical onset: Diagnostic value of biomarkers
por: Novakova, Lenka, et al.
Publicado: (2018)

New data identify an increasing sex ratio of multiple sclerosis in Sweden
por: Westerlind, Helga, et al.
Publicado: (2014)

A nationwide survey of the influence of month of birth on the risk of developing multiple sclerosis in Sweden and Iceland
por: Eliasdottir, Olöf, et al.
Publicado: (2017)

T-lymphocyte subset abnormalities in the Guillain-Barré syndrome
por: Dahle, C., et al.
Publicado: (1994)

The Swedish MS registry – clinical support tool and scientific resource
por: Hillert, J, et al.
Publicado: (2015)

Inflammation-related plasma and CSF biomarkers for multiple sclerosis
por: Huang, Jesse, et al.
Publicado: (2020)

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
por: Novakova, Lenka, et al.
Publicado: (2017)

Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis
por: Mellergård, Johan, et al.
Publicado: (2012)

Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing–remitting multiple sclerosis: an observational study
por: Zhukovsky, Christina, et al.
Publicado: (2021)

Increased B Cell and Cytotoxic NK Cell Proportions and Increased T Cell Responsiveness in Blood of Natalizumab-Treated Multiple Sclerosis Patients
por: Mellergård, Johan, et al.
Publicado: (2013)

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy
por: Salzer, Jonatan, et al.
Publicado: (2016)

MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
por: Jernås, Margareta, et al.
Publicado: (2013)

Subacute neuronopathy in a young man: a possible association with tetracycline treatment
por: Vrethem, Magnus, et al.
Publicado: (2011)

Intrathecal kappa free light chain synthesis is associated with worse prognosis in relapsing–remitting multiple sclerosis
por: Rosenstein, Igal, et al.
Publicado: (2023)

Association between brain volume and disability over time in multiple sclerosis
por: Moridi, Thomas, et al.
Publicado: (2022)

A five-year observational prospective mono-center study of the efficacy of alemtuzumab in a real-world cohort of patients with multiple sclerosis
por: Sandgren, Sofia, et al.
Publicado: (2023)

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
por: Vågberg, M., et al.
Publicado: (2016)

No increase of serum neurofilament light in relapsing-remitting multiple sclerosis patients switching from standard to extended-interval dosing of natalizumab
por: Johnsson, Magnus, et al.
Publicado: (2022)

High Interferon-γ Uniquely in Vδ1 T Cells Correlates with Markers of Inflammation and Axonal Damage in Early Multiple Sclerosis
por: Singh, Avadhesh Kumar, et al.
Publicado: (2017)

Safety of Alemtuzumab and Autologous Hematopoietic Stem Cell Transplantation Compared to Noninduction Therapies for Multiple Sclerosis
por: Alping, Peter, et al.
Publicado: (2021)

The role of autoimmune antibodies to predict secondary autoimmunity in patients with relapsing-remitting multiple sclerosis treated with alemtuzumab: A nationwide prospective survey
por: Sandgren, Sofia, et al.
Publicado: (2023)

Cerebrospinal fluid growth-associated protein 43 in multiple sclerosis
por: Sandelius, Åsa, et al.
Publicado: (2019)

Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse
por: McKay, Kyla A., et al.
Publicado: (2022)

Increased prevalence of celiac disease in idiopathic inflammatory myopathies
por: Danielsson, Olof, et al.
Publicado: (2017)

Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
por: Håkansson, Irene, et al.
Publicado: (2018)

SARS‐COV‐2 a trigger of myelin oligodendrocyte glycoprotein‐associated disorder
por: Johnsson, Magnus, et al.
Publicado: (2022)

Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden
por: Wickström, Anne, et al.
Publicado: (2015)

Polymorphisms of GSTT1, GSTM1, and EPHX genotypes in patients with cryptogenic polyneuropathy: a case–control study
por: Lindh, Jonas, et al.
Publicado: (2011)

The romantic Swedish organ works by Sjögren, Fryklöf, Olsson and Lindberg /
por: Fagius, Hans, 1951-
Publicado: (1992)

A Sensitive Method for Detecting Peptide-specific CD4(+) T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis
por: Sharma, Sapna, et al.
Publicado: (2017)

The Concept and Practice of Immunomodulation in Ayurveda and the Role of Rasayanas as Immunomodulators
por: Tripathi, J.S., et al.
Publicado: (1999)

Immunomodulators for Asthma
por: Dimov, Vesselin V, et al.
Publicado: (2010)

Urinary 2,5-hexanedione excretion in cryptogenic polyneuropathy compared to the general Swedish population
por: Persson, Bodil, et al.
Publicado: (2013)

"Raising a Ghost It Were Better to Lay"
por: Hawthorne, C. O.
Publicado: (1917)

"Raising a Ghost It Were Better to Lay"
por: Hawthorne, C. O.
Publicado: (1917)

"Raising a Ghost It Were Better to Lay"
por: Hawthorne, C. O.
Publicado: (1917)

Potential Application of Tregitopes as Immunomodulating Agents in Multiple Sclerosis
por: Elyaman, Wassim, et al.
Publicado: (2011)

Helminth Immunomodulation in Autoimmune Disease
por: Smallwood, Taylor B., et al.
Publicado: (2017)

Schistosome immunomodulators
por: Acharya, Sreemoyee, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jmg1le29m4km10nl9s4ajsdisj